IP Library Granted Patent US 12,440,455
Granted Patent B2
US 12,440,455 · App. 18/169,155 · Granted Oct 14, 2025

Methods of administering cannabinoids

Inventors: James Lowder (San Diego, CA); Ramon Seva (San Diego, CA); Vassili Kotlov (San Diego, CA)
Assignee: IMPACT NATURALS, INC.
A61K31/05A61K31/352A61K47/543
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,455
App. No.
18/169,155
Granted
Oct 14, 2025
Kind
B2
Abstract

The disclosure provides compositions and methods of treatment by enhanced delivery of cannabinoids using cannabinoid-infused powders comprising a cannabinoid API, an edible carrier, and an edible oil comprising long chain triglycerides.

Claims (6)

1. A method of enhancing delivery of a cannabinoid to the central nervous system; comprising orally administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising a cannabinoid-infused powder, wherein the cannabinoid-infused powder comprises a cannabinoid active pharmaceutical ingredient (API) in an amount of (a) 4%-6% CBD and (b) 0.2% to 0.7% CBG and/or 0.2% to 0.7% CBN, by weight of the cannabinoid-infused powder; an edible oil consisting of 5-10% sunflower seed oil, by weight of the cannabinoid-infused powder; and an edible carrier selected from silicon dioxide, starch, dried plant material and mixtures thereof, wherein the edible carrier comprises 80%-90% by weight of the cannabinoid infused powder, and wherein the cannabinoid-infused powder does not contain any additional oil.

2. The method of claim 1 wherein

the API comprises 5.8%, by weight of the cannabinoid-infused powder;

the edible oil consists of 5.8% sunflower seed oil, by weight of the cannabinoid-infused powder; and

the edible carrier is selected from silicon dioxide, starch, and mixtures thereof, and comprises 88.4% by weight of the cannabinoid infused powder.

3. The method of claim 1 , wherein the pharmaceutical composition further comprises melatonin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023
From: LOWDER, JAMES; SEVA, RAMON; KOTLOV, VASSILI
To: IMPACT NATURALS, INC.
Reel/Frame 063596/0188 →
Continuity (2)
Provisional Application 63309929 · Feb 14, 2022
Related Publication 20230255901A1 · Aug 17, 2023
References Cited (19)
US 10756180B2 · Reillo et al. · 2020 [cited by applicant]
US 20140357708A1 · Murty · 2014 [cited by examiner]
US 20190298683A1 · Friedman · 2019 [cited by applicant]
US 20200246404A1 · Yucel et al. · 2020 [cited by applicant]
US 20210069103A1 · Le Devedec et al. · 2021 [cited by applicant]
WO WO2015025312A1 · 2015 [cited by examiner]
WO WO2016022936 · 2016 [cited by applicant]
WO WO2018152334A1 · 2018 [cited by examiner]
WO WO2020212976 · 2020 [cited by applicant]
Stella et al. Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain, (Drugs, 81: 1513-1557). (Year: 2021). [cited by examiner]
Leyva-Gutierrez et al. Characterization of By-Products from Commercial Cannabidiol Production (Journal of Agricultural and Food Chemistry, 68, 7648-7659) (Year: 2020). [cited by examiner]
Grijo et al. Supercritical Extraction Strategies Using CO2 and Ethanol to Obtain Cannabinoid Compounds from Cannabis Hybrid Flowers (Journal of CO2 Utilization 30, 241-248). (Year: 2019). [cited by examiner]
Gervajio, Fatty Acids and Derivatives from Coconut Oil (Kirk-Othmer Chemical Technology of Cosmetics, p. 445-458). (Year: 2013). [cited by examiner]
Caddeo et al. A Neuroendocrine Therapeutic Approach with the Pineal Hormone Melatonin, Cannabidiol, and Oxytocin in the Treatment of the Autism Spectrum disorders (J Immuno Allerg. 1(2): 1-7). (Year: 2020). [cited by examiner]
Nguyen, et al., “Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses”, [cited by applicant]
Horst HJ, Höltje WJ, Dennis M, Coert A, Geelen J, Voigt KD. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr. Sep. 15, 1976;54(18):875-9. doi: 10.1007/BF0148358… [cited by applicant]
Knaub, et al., “A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects”, [cited by applicant]
Shackleford et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dog… [cited by applicant]
Zhang, Zichen et al. “An update on oral drug delivery via intestinal lymphatic transport.” [cited by applicant]